03.06.2013 - GlaxoSmithKline’s multi kinase blocker pazopanib has increased progression free survival in women with advanced ovarian cancer by 5.6 months.
At the ASCO meeting, the British drug major reported that the median time to disease progression under the VEGFR, PDGFR, c-KIT blocker post-surgery and chemotherapy was 17.9 months, compared with 12.3 months in patients receiving placebo. GSK announced that it will file an MAA in the US for pazopanib as first-in-class maintenance therapy after surgery and chemotherapy. In contrast to Europe where Roche’s bevacizumab is approved as maintenance therapy, there is no comparable treatment approved by the FDA.
91% of the 940 patients with advanced epithelial ovarian cancer had stage III/IV disease at diagnosis and no residual disease following surgery. While efficacy was shown, more serious adverse drug effects were observed in the pazopanib group (26%) than in the placebo arm (11%) of the study.
23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.
15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.
11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.
04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.
The First Multi-Angle Light Scattering Detector for UHPLC!
The µDAWN™ Multi-Angle static Light Scattering (MALS) detector performs absolute characterization of macromolecules eluting from UHPLC, determining molar mass and size independently of retention time and molecular reference standards. more